Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Targeting of preexisting and induced breast cancer stem cells with trastuzumab and trastuzumab emtansine (T-DM1).

Cell death & disease - 27 Mar 2014

Diessner J, Bruttel V, Stein R G, Horn E, Häusler S F M, Dietl J, Hönig A, Wischhusen J

Abstract excerpt

The antibody trastuzumab (Herceptin) has substantially improved overall survival for patients with aggressive HER2-positive breast cancer. However, about 70% of all treated patients will experience relapse or disease progression. This may be related to an insufficient targeting of the CD44(high)CD24(low) breast cancer stem cell subset, which is not only highly resistant to chemotherapy and radiotherapy but also a...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal, Humanized
Share to Antibody-Dependent Cell Cytotoxicity

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Autophagy

Share to Coculture Techniques

Share to Endocytosis

Share to Neoplastic Stem Cells

Share to Receptor, ErbB-2

Share to Trastuzumab

Source

Open in PubMed Open full text

Identifiers

PMID: 24675467
DOI: 10.1038/cddis.2014.115
PMCID: PMC3973200

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeting of preexisting and induced breast cancer stem cells with trastuzumab and trastuzumab emtansine (T-DM1).PMID 24675467Read ↗

Immunoselection of breast and ovarian cancer cells with trastuzumab and natural killer cells: selective escape of CD44high/CD24low/HER2low breast cancer stem cells.Semantic proximity Read ↗

The anti-diabetic drug metformin suppresses self-renewal and proliferation of trastuzumab-resistant tumor-initiating breast cancer stem cells.Semantic proximity Read ↗

HER-2, Notch, and Breast Cancer Stem Cells: Targeting an Axis of EvilSemantic proximity Read ↗

Basal/HER2 breast carcinomasSemantic proximity Read ↗

A Monoclonal Antibody against Human Notch1 Ligand–Binding Domain Depletes Subpopulation of Putative Breast Cancer Stem–like CellsSemantic proximity Read ↗

miR-200c suppresses stemness and increases cellular sensitivity to trastuzumab in HER2+ breast cancerSemantic proximity Read ↗

Cancer stem cell-driven efficacy of trastuzumab (Herceptin): towards a reclassification of clinically HER2-positive breast carcinomas.Semantic proximity Read ↗

miR‐200c suppresses stemness and increases cellular sensitivity to trastuzumab in HER2+ breast cancerSemantic proximity Read ↗

Combinatorial treatment of mammospheres with trastuzumab and salinomycin efficiently targets HER2‐positive cancer cells and cancer stem cellsSemantic proximity Read ↗

In vitro and in vivo antiproliferative activity of metformin on stem-like cells isolated from spontaneous canine mammary carcinomas: translational implications for human tumors.Semantic proximity Read ↗

Sphere formation reverses the metastatic and cancer stem cell phenotype of the murine mammary tumour 4T1, independently of the putative cancer stem cell marker Sca-1.Semantic proximity Read ↗

Trastuzumab (herceptin) targets gastric cancer stem cells characterized by CD90 phenotype.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.